Colorectal Cancer

Colon Cancer Mutations; KRAS, BRAF V600E Effect Survival Rates

January 19, 2016

For patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin (FOLFOX), KRAS and BRAF V600E mutations are associated with worse clinical outcome in patients with microsatellite-stable tumors, according to a study published online in JAMA Oncology.